Table 3.
ANOVAs for clinical secondary outcome measures “on-medication” across all three time assessments.
| ANOVA | |||
|---|---|---|---|
| Measures | Effect of time | Effect of group | Time × Group interaction effect |
| MDS-UPDRS-MS | F(2,48) = 8.36, p = 0.002 (ES = 0.26) | F(1,24) = 0.15, p = 0.7 (N/S) | F(2,48) = 3.51, p = 0.03 (ES = 0.13) |
| MDS-UPDRS-SS | F(2,48) = 13.46, p = 0.000 (ES = 0.36) | F(1,24) = 0.32, p = 0.7 (N/S) | F(2,48) = 7.64, p = 0.005 (ES = 0.24) |
| MDS-UPDRS-M-DL | F(2,48) = 4.34, p = 0.01 (ES = 0.15) | F(1,24) = 0.22, p = 0.7 (N/S) | F(2,48) = 5.58, p = 0.01 (ES = 0.19) |
| MDS-UPDRS-NM-DL | F(2,48) = 4.98, p = 0.01 (ES = 0.17) | F(1,24) = 0.55, p = 0.7 (N/S) | F(2,48) = 2.14, p = 0.13, (N/S) |
| PDQ-39 | F(2,48) = 4.46, p = 0.02 (ES = 0.16) | F(1,24) = 1.91, p = 0.7 (N/S) | F(2,48) = 3.79, p = 0.03 (ES = 0.14) |
ANOVA, Analysis of variance; MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; MS, motor subscale; SS, summed score; M-DL, Motor aspects of daily living; NM-DL, non motor aspects of daily living; PDQ, Parkinson’s disease questionnaire; ES, effect size; N/S, not significant; P-values are FDR corrected.